The sympathetic nervous system: Anatomy and receptor pharmacology

Published on 07/02/2015 by admin

Filed under Anesthesiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 5288 times

The sympathetic nervous system: Anatomy and receptor pharmacology

James D. Hannon, MD

Anatomy

The sympathetic nervous system (SNS) is widely distributed throughout the body. Although afferent pathways exist and are important in relaying visceral sensory information to the central nervous system, the most clearly defined portions of the SNS are the efferent preganglionic and postganglionic fibers and their associated paravertebral ganglia. The cell bodies that give rise to the preganglionic fibers of the SNS lie in the intermediolateral columns of the thoracolumbar spinal cord from T1 to L2 or L3 (hence, the SNS is sometimes referred to as the thoracolumbar nervous system).

The short myelinated preganglionic fibers leave the spinal cord in the anterior nerve roots, form white rami, and synapse in sympathetic ganglia lying in three locations outside the cerebrospinal axis. The gray rami arise from the ganglia and carry postganglionic fibers back to the spinal nerves for distribution to the sweat glands, pilomotor muscles, and blood vessels of the skin and skeletal muscle (Figure 40-1). The 22 sets of paravertebral ganglia are paired on either side of the vertebral column, connected to the spinal nerves by the white and gray rami communicans, and interconnected by nerve trunks to form the lateral chains. They include the upper and middle cervical ganglia, the stellate ganglia (fusion of inferior cervical and T1 ganglia), and the ganglia of the thoracic, abdominal, and pelvic sympathetic trunks. Unpaired prevertebral ganglia are found in the abdomen and pelvis near the ventral surface of the vertebral column. They are named according to the major branches of the aorta: for example, celiac, renal, and superior and inferior mesenteric ganglia. The terminal ganglia lie near the innervated organs (cervical ganglia in the neck, rectum, and bladder).

The cells of the adrenal medulla are analogous to sympathetic ganglia, except that the postganglionic cells have lost their axons and secrete norepinephrine, epinephrine, and dopamine directly into the bloodstream. Preganglionic fibers may pass through several paravertebral ganglia and synapse with multiple neurons in a ganglion, a characteristic that leads to a diffused output. Postganglionic fibers arising from the sympathetic ganglia may receive input from several preganglionic fibers and innervate visceral structures in the head, neck, thorax, and abdomen. They may pass to target organs through a nerve network along blood vessels or rejoin a mixed peripheral nerve.

Receptor pharmacology

Neurotransmitters

Acetylcholine is the neurotransmitter of all preganglionic sympathetic fibers, including those that innervate the cells of the adrenal medulla. Norepinephrine is released by nearly all sympathetic postganglionic nerve endings; exceptions are the postganglionic cholinergic fibers that innervate sweat glands (sudomotor) and blood vessels in skeletal muscles (vasomotor). Increasing evidence indicates that neurons in the peripheral nervous system release two or more transmitters from individual nerve terminals when stimulated. Substances released with norepinephrine, such as adenosine triphosphate, may function as cotransmitters or neuromodulators of the response to norepinephrine.

Synthesis, storage, release, and inactivation of norepinephrine

The main site of norepinephrine synthesis is in the postganglionic nerve terminal. Tyrosine is transported actively into the axoplasm and converted to dihydroxyphenylalanine (rate-limiting step) and then to dopamine by cytoplasmic enzymes. Dopamine is transported into storage vesicles, where it is converted to norepinephrine (Figure 40-2). Exocytosis of norepinephrine is triggered by the increased intracellular calcium that accompanies an action potential. Active reuptake (uptake 1) of norepinephrine into the presynaptic terminal terminates the effect of norepinephrine at the effector site. This process accounts for nearly all of the released norepinephrine, which is then stored in vesicles for reuse. Monoamine oxidase is responsible for metabolism of the small amount of norepinephrine that enters the cytoplasm after neuronal reuptake without being taken up into vesicles. Monoamine oxidase and catechol-O-methyltransferase are responsible for metabolism of norepinephrine that is not reabsorbed into neurons.

Receptor subtypes

Acetylcholine activates nicotinic cholinergic receptors in the sympathetic ganglia and adrenal medulla. The primary sympathetic postganglionic neurotransmitter is norepinephrine. Epinephrine, the circulating hormone released by the adrenal medulla, and dopamine, the neurotransmitter of the less well characterized dopaminergic system, are the other naturally occurring catecholamines that interact with peripheral adrenergic receptors. The adrenergic receptors were initially classified as α and β according to their responsiveness to norepinephrine and epinephrine. Subsequent discovery of more selective agonists and antagonists allowed the α receptors to be subdivided into α1 and α2 and the β receptors into β1, β2, and β3. Peripheral dopamine receptors have also been discovered; these are classified as DA1 or DA2. α1-Receptors are found in the smooth muscle of blood vessels (contraction), the genitourinary system (contraction), and the intestine (relaxation) and in the liver (glycogenolysis, gluconeogenesis) and heart (increased contractile force, arrhythmias). α2-Receptors are located in the pancreatic β cells (decreased insulin secretion), platelets (aggregation), nerve terminals (decreased norepinephrine release), and vascular smooth muscle (contraction). β1-Receptors are found in the heart (increased force and rate of contraction and atrioventricular node conduction) and juxtaglomerular cells (increased renin secretion); β2-receptors are in smooth muscles of the vascular, bronchial, gastrointestinal, and genitourinary systems (relaxation) and in skeletal muscle (glycogenolysis, uptake of K+) and the liver (glycogenolysis, gluconeogenesis); and β3-receptors, in adipose tissue (lipolysis).

Agonists

Sympathomimetic amines

β-Phenylethylamine can be considered the parent compound. Compounds with hydroxyl groups at positions 3 and 4 of the benzene ring are called catechols; catecholamines are catechols with an ethylamine side chain. Many directly acting sympathomimetic amines stimulate both α and β receptors (Table 40-1). The ratio of activities varies among agonists along a spectrum from predominantly α (phenylephrine) to predominantly β (isoproterenol). β-Receptor selectivity is enhanced by substitution of the amine group. Table 40-2 lists the antagonists of the adrenergic receptors, and Table 40-3 lists drugs that have a unique mechanism of action within the SNS.

Table 40-1

Adrenergic Agonists

  Mode of Action  
Agent α1 α2 β1 β2 DA1 DA2 Dose
Natural
Norepinephrine ++++ +++ ++ +++     0.05-0.3 μg·kg−1·min−1
Epinephrine +++ ++ +++ +++ +   0.05-0.2 μg·kg−1·min−1
Dopamine              
Low dose         ++++ ++ 1-5 μg·kg−1·min−1
Medium dose + ? ++ + ++++   5-15 μg·kg−1·min−1
High dose +++ ? ++ +     > 15 μg·kg−1·min−1
Synthetic
Metaproterenol     + ++++     MDI
Albuterol       ++++     MDI
Terbutaline       ++++     MDI
Isoproterenol +   ++++ ++++     0.01-0.2 μg·kg−1·min−1
Dobutamine +   +++ +     2.5-15 μg·kg−1·min−1
Mephentermine ++ ? +++ ?     0.1-0.5 mg/kg
Ephedrine ++ ? ++ +     0.2-1.0 mg/kg
Metaraminol ++++ ? ++ ?     10-102 μg/kg
Phenylephrine ++++   +       1-10 μg·kg−1·min−1
Methoxamine ++++           0.05-0.2 mg/kg
Dopexamine       ++ +++ + 1-6 μg·kg−1·min−1
Fenoldopam         +++   0.1-0.8 μg·kg−1·min−1

image

++++, tremendous stimulation; +++, marked stimulation; ++, moderate stimulation; +, slight stimulation; ?, unknown.

DA, Dopamine; MDI, metered-dose inhaler.

Table 40-2

Antagonists of the Adrenergic Receptors

Receptor Drug
α1 = α2 (nonselective) Phenoxybenzamine (irreversible), phentolamine, tolazoline
α1 Prazosin, terazosin, doxazosin, trimazosin
α2 Yohimbine
β1 = β2 (nonselective) Propranolol, timolol, nadolol, pindolol, sotalol, labetalol (weak α1)
β1 Metoprolol, atenolol, esmolol, acebutolol
β2 Butoxamine
β3 BRL 37344

Table 40-3

Drugs with Unique Mechanisms of Action Within the Adrenergic System

Drug Action
Labetalol α1-Receptor selective and a more potent nonselective β-receptor blocker (5-10 times α1 over β)
Carvedilol α1-Receptor selective and a more potent nonselective β-receptor blocker
Bretylium Blocks NE release
Propafenone β-Adrenergic receptor antagonist
Reserpine Blocks vesicular uptake of NE
Guanethidine Causes active release and then depletion of NE
Cocaine Blocks neuronal reuptake of NE
TCA Blocks neuronal reuptake of NE
Tyramine Causes release of vesicular and nonvesicular stores of catecholamines

NE, Norepinephrine; TCA, tricyclic antidepressant.